Literature DB >> 2522846

Human antibody responses to bacteriophage phi X 174: sequential induction of IgM and IgG subclass antibody.

K H Pyun1, H D Ochs, R J Wedgwood, X Q Yang, S R Heller, C B Reimer.   

Abstract

We studied the appearance of antigen-specific immunoglobulin classes and IgG subclasses in normal adult human subjects in response to primary, secondary, and tertiary immunization with the T-cell-dependent neo-antigen bacteriophage phi X 174. To complete the study we developed a sensitive, specific, and reproducible ELISA assay which was closely comparable to the widely used neutralization assay for total antibody (r = +0.97) and for IgG antibody (r = +0.93), and reasonably comparable for IgM antibody (r = +0.76). We confirmed that the initial response to primary immunization was predominantly, but not exclusively, IgM antibody. The secondary and tertiary responses demonstrated memory, amplification, and switch from IgM to IgG antibody. There was an orderly appearance of phage-specific IgG subclasses. IgG3 and IgG1 antibodies appeared 2 to 6 weeks after primary immunization. In all subjects there was a marked increase in IgG1 and IgG3 antibody after secondary immunization, and IgG2 antibody followed closely; IgG4 antibody appeared in some subjects. IgM antibody persisted in significant amounts (approx 50%) throughout the secondary response period. Following tertiary immunization, IgG1, IgG2, and IgG3 antibody consistently increased, and IgG4 antibody appeared in all subjects; IgG1 antibody predominated. Low levels of IgM antibody (approx 1% of total) persisted during the tertiary response. The persisting antibody on long-term follow-up (median 4 years after immunization) was virtually all (greater than 90%) IgG1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522846     DOI: 10.1016/0090-1229(89)90024-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  6 in total

1.  Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient.

Authors:  Ping Liu; Ines Santisteban; Lauri M Burroughs; Hans D Ochs; Troy R Torgerson; Michael S Hershfield; David J Rawlings; Andrew M Scharenberg
Journal:  Clin Immunol       Date:  2008-10-25       Impact factor: 3.969

2.  Induction of Phage-Specific Antibodies by Two Therapeutic Staphylococcal Bacteriophages Administered per os.

Authors:  Joanna Majewska; Zuzanna Kaźmierczak; Karolina Lahutta; Dorota Lecion; Aleksander Szymczak; Paulina Miernikiewicz; Jarosław Drapała; Marek Harhala; Karolina Marek-Bukowiec; Natalia Jędruchniewicz; Barbara Owczarek; Andrzej Górski; Krystyna Dąbrowska
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

3.  The dark side of the gut: Virome-host interactions in intestinal homeostasis and disease.

Authors:  Yuhao Li; Scott A Handley; Megan T Baldridge
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

4.  Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Authors:  D M C Brinkman; C M Jol-van der Zijde; M M ten Dam; J M Vossen; A D M E Osterhaus; F P Kroon; M J D van Tol
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.542

5.  B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells.

Authors:  S Nonoyama; D Hollenbaugh; A Aruffo; J A Ledbetter; H D Ochs
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

6.  Diagnostic Immunization with Bacteriophage ΦX 174 in Patients with Common Variable Immunodeficiency/Hypogammaglobulinemia.

Authors:  Lauren L Smith; Rebecca Buckley; Patricia Lugar
Journal:  Front Immunol       Date:  2014-08-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.